Akcea
NICE rules against the use of Akcea’s Waylivra in the NHS
January 3, 2020Medical Communications Akcea, European Commission, FCS, NHS, NICE
NICE has not recommended Akcea’s drug Waylivra (volanesorsen) to be used for the treatment of Familial Chylomicronaemia Syndrome (FCS) in …
NICE recommends Akcea’s Tegsedi for rare, life-threatening progressive disease
April 17, 2019Research and Development, Sales and Marketing Akcea, NHS, NICE, Tegsedi, UK
Akcea Therapeutics has shared the news that Tegsedi (inotersen), its antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production, has …
Akcea and Ionis’ Waylivra nets CHMP approval in ultra-rare familial chylomicronaemia syndrome
March 5, 2019Manufacturing and Production, Sales and Marketing Akcea, FCS, Ionis, familial chylomicronemia syndrome, pharma, rare disease
Akcea Therapeutics and Ionis Pharmaceuticals have announced that their investigational therapy Waylivra (volanesorsen) has been recommended by the EMA’s Committee …
Akcea cuts 10% of staff following FDA rejection
September 10, 2018Manufacturing and Production, Sales and Marketing Akcea, FDA, Waylivra, pharma
Akcea Therapeutics has been hit hard by the FDA’s decision to reject its drug Waylivra (volanesorsen) for the treatment of …
Ionis/Akcea’s ultra-rare disease drug rejected by FDA
August 28, 2018Manufacturing and Production, Sales and Marketing Akcea, FDA, Ionis, familial chylomicronemia syndrome, pharma, rare disease
The FDA has opted to refuse approval to Akcea and Ionis’ Waylivra (volanesorsen) for the treatment of the ultra-rare hereditary …
Novartis and Ionis enter $1bn cardiovascular drug deal
January 6, 2017Medical Communications, Research and Development, Sales and Marketing Akcea, Akcea Therapeutics, Ionis, Ionis Pharmaceuticals, cardiovascular
Ionis Pharmaceuticals and one of its wholly-owned subsidiaries Akcea Therapeutics have entered into a partnership with Novartis worth potentially more …
Ionis achieves successful Phase 3 trial to treat rare diseases
December 19, 2016Manufacturing and Production, Research and Development Akcea, Ionis, rare disease
Ionis Pharmaceutial announced that the results of a Phase 3 trial into its treatment for hypertriglyceridemia met its primary endpoint. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
